Novel partnership fosters shared expertise while integrating diagnostic and data-driven solutions to accelerate antimicrobial stewardship in pediatric care
SALT LAKE CITY (Dec. 6, 2023) – Texas Children’s Hospital, a nonprofit health care organization, is the newest facility inducted into the bioMérieux global Antimicrobial Stewardship Center of Excellence program. bioMérieux, a world leader in in vitro diagnostics, is proud to partner with Texas Children’s. The partnership symbolizes a collective commitment to continued excellence in managing AMR by advancing antimicrobial stewardship (AMS) with cutting-edge solutions.
Texas Children’s and bioMérieux will work together to further activate specific AMS initiatives that will improve patient care, while leveraging shared expertise to develop and scale innovative best practices based on the application of game-changing diagnostic technology. The collaboration aims to curb the dangers associated with AMR, such as the transmission of multi-drug resistant organisms (MDROs).
“This is not merely a recognition – it symbolizes a profound partnership with Texas Children’s,” said Jennifer Zinn, Executive Vice President, Clinical Operations, bioMérieux. “We are committed to empowering robust stewardship interventions and capturing real-world evidence of their effects on patient outcomes and healthcare costs. In collaboration with Texas Children’s, we aim to emphasize industry best practices in diagnostic stewardship. Leveraging our clinical diagnostic portfolio, medical education, lab consultancy services, and information technology solutions, we aspire to fortify AMS initiatives even further.”
AMR is a major concern for pediatricians globally. Because children have weaker immune systems, this particular group is more vulnerable to infections and diseases. To combat AMR among younger populations, a holistic focus on AMS in pediatrics is essential.
“By collaborating with bioMérieux, we can deliver diagnostic-driven insights that directly impact patient therapy and accelerate our stewardship program impact,” said Dr. James Versalovic, Pathologist-in-Chief at Texas Children’s Hospital and Director of Texas Children’s Microbiome Center and a Milton J. Finegold Professor and Vice Chair, Pathology & Immunology, Baylor College of Medicine. “Our teams work diligently to engage all Texas Children’s stakeholders in our AMS initiatives. We want to set the best possible example for other health systems that might be figuring out how to get started or overcome barriers. Together, we can all make a difference in the fight against AMR.”
Texas Children’s is now one of three health systems in North America to join bioMérieux’s global Antimicrobial Stewardship Center of Excellence initiative. Texas Children’s has consistently been ranked as the No. 1 children’s hospital in Texas and placed third nationally in the U.S. News & World Report 2023-2024 Best Children’s Hospitals report.
ABOUT GLOBAL ANTIMICROBIAL STEWARDSHIP CENTERS OF EXCELLENCE
In 2021, bioMérieux established the Antimicrobial Stewardship Centers of Excellence program to bring attention to the threat of antimicrobial resistance and to accelerate the impact that infectious diseases diagnostics have in facilitating antimicrobial stewardship and better patient care. bioMérieux has formalized partnerships with 13 hospitals globally, including sites in the United States, India, China, Malaysia, Morocco, France, Italy, Colombia, Chile, Mexico and Kenya. These sites are leaders in their countries and regions in regards to integrating diagnostics into antimicrobial stewardship. The partnerships will focus on generating and showcasing real-world medical and economic data and best practices about the value of combining diagnostics, medical education, lab consultancy services, and information technology solutions.
ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2022, revenues reached €3.6 billion, with over 90% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in food, pharmaceutical and cosmetic products. www.biomerieux.com.
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
MEDIA CONTACTS
Media Relations
bioMérieux
Liza Deckelbaum
Tel.: 919.645.0782